Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 10/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052262 | 0.85 | ABL1 (0.52) | ABL1DDR2WEE1BRAFRAF1 | |
| SCHEMBL5056340 | 0.84 | MAPK14 (0.46) | DDR2BRAFRAF1SYKMAPK14 | |
| SCHEMBL5060642 | 0.83 | DDR2 (0.47) | DDR2BRAFRAF1SYKMAPK14 | |
| SCHEMBL5056346 | 0.83 | ABL1 (0.53) | ABL1DDR2BRAFRAF1SYK | |
| SCHEMBL5052196 | 0.83 | ABL1 (0.56) | ABL1DDR2BRAFRAF1SYK | |
| SCHEMBL5052319 | 0.83 | DDR2 (0.46) | DDR2BRAFRAF1SYKMAPK14 | |
| SCHEMBL5062066 | 0.83 | RAF1 (0.46) | WEE1BRAFRAF1SYKMAPK14 | |
| SCHEMBL4420794 | 0.83 | SYK (0.52) | DDR2BRAFRAF1SYKMAPK14 | |
| SCHEMBL5062298 | 0.83 | DDR2 (0.47) | DDR2BRAFRAF1SYKMAPK14 | |
| SCHEMBL5056424 | 0.82 | ABL1 (0.45) | ABL1WEE1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | ABL1 20/4885DDR2 1256/4885WEE1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.